Founded Year

2014

Stage

Series E | Alive

Total Raised

$524.8M

Valuation

$0000 

Last Raised

$123M | 10 mos ago

Revenue

$0000 

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+41 points in the past 30 days

About Insilico Medicine

Insilico Medicine focuses on artificial intelligence in drug discovery and development. The company provides artificial intelligence platforms for multi-omics target discovery, deep biology analysis, automated drug design, and predicting outcomes in clinical trials. The technologies are intended to assist in the process of discovering and developing new medications for various diseases. It was founded in 2014 and is based in New Territories, Hong Kong.

Headquarters Location

Phase 2, Hong Kong Science Park, Pak Shek Kok Unit 310, 3rd Floor, Building 8W

New Territories,

Hong Kong

Loading...

Insilico Medicine's Product Videos

ESPs containing Insilico Medicine

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare & Life Sciences / Drug R&D Tech

The cellular rejuvenation therapeutics market includes companies developing therapies that target key hallmarks of aging such as cellular senescence, telomere attrition, and mitochondrial dysfunction. These interventions include senolytics that remove damaged cells, telomere-targeting therapies that maintain chromosome integrity, and mitochondrial treatments that optimize cellular energy productio…

Insilico Medicine named as Leader among 15 other companies, including Juvenescence, Rubedo, and Shift Bioscience.

Insilico Medicine's Products & Differentiators

    Pharma.AI

    Global’s first end-to-end generative Al software and robotics platform designed to improve the quality and productivity of pharmaceutical research, currently commercially-available

Loading...

Research containing Insilico Medicine

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Insilico Medicine in 21 CB Insights research briefs, most recently on Sep 19, 2025.

Expert Collections containing Insilico Medicine

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Insilico Medicine is included in 7 Expert Collections, including AI 100 (All Winners 2018-2025).

A

AI 100 (All Winners 2018-2025)

199 items

Winners of CB Insights' annual AI 100, a list of the 100 most promising AI startups in the world.

A

Artificial Intelligence (AI)

25,765 items

Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.

D

Digital Health 50

150 items

The winners of the second annual CB Insights Digital Health 150.

D

Digital Health

12,122 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

D

Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

G

Generative AI

2,951 items

Companies working on generative AI applications and infrastructure.

Insilico Medicine Patents

Insilico Medicine has filed 71 patents.

The 3 most popular patent topics include:

  • transcription factors
  • proteins
  • clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/6/2023

2/18/2025

Trifluoromethyl compounds, Transcription factors, Designer drugs, Prodrugs, Cannabinoids

Grant

Application Date

7/6/2023

Grant Date

2/18/2025

Title

Related Topics

Trifluoromethyl compounds, Transcription factors, Designer drugs, Prodrugs, Cannabinoids

Status

Grant

Latest Insilico Medicine News

$14.97 Bn AI in Biotechnology Market Growth Trends, Opportunities, and Forecasts, 2025-2033 - Rising Biological Data Volumes and Demand for Faster Drug Discovery and Personalized Medicine - ResearchAndMarkets.com

Nov 4, 2025

The global AI in biotechnology market was valued at USD 3.23 billion in 2024, and is expected to reach USD 14.97 billion by 2033, rising at a CAGR of 21.1% during the forecast period. This new 2025 market report presents an in-depth assessment of the global AI in biotechnology market dynamics, opportunities, future road map, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook in the global AI in biotechnology market. The report also provides up-to-date historical market size data for the period 2022 - 2024 and an illustrative forecast to 2033 covering key market aspects like market value, share, analysis, and trends for the global AI in biotechnology market. The integration of artificial intelligence (AI) within the biotechnology sector is transforming how companies approach research and development. By leveraging advanced data analytics and machine learning algorithms, biotechnology firms can enhance their capabilities, optimize processes, and ultimately improve outcomes. Such technology is not merely a trend but a significant evolution in the industry. The report provides a detailed analysis of the current industry situation and market requirements, highlighting facts about the market size, market share, revenue for global AI in biotechnology market segments, and a vivid forecast to 2033. It also provides a comprehensive analysis of the pricing landscape, policies and regulation, and reimbursement pattern by countries and region. The report also offers analysis and information according to categories such as market segments, product offering, end-user, function, deployment, geographies, companies and competitive landscape. The report also provides a detailed description of the porter's five forces analysis, SWOT analysis, funding, merger and acquisitions, pipeline, growth drivers and challenges of the global AI in biotechnology market. An in-depth analysis of the main competitors in the industry has been conducted to offer insights into their business profiles, services, primary strategies, contracts, alliances, agreements, new service introductions, mergers and acquisitions, and recent events related to the AI in biotechnology market. This report covers the competitive analysis of new startups in the AI in biotechnology market ecosystem. Additionally, the research also addresses industry-specific trends like technology assessment, ecosystem and market analysis, as well as the patent and regulatory environment, among others. AI in Biotechnology Market Growth Drivers Several factors are driving the growth of AI in the biotechnology market. First, the increasing volume of biological data necessitates advanced analytical tools. Traditional methods are often insufficient to process and interpret large datasets, highlighting the essential role of AI. Furthermore, AI-driven technologies enable faster drug discovery and personalized medicine, streamlining the path from laboratory to market. Looking ahead, the synergy of AI and biotechnology is poised to unlock new discoveries and efficiency gains, solidifying its importance in the healthcare landscape. Key Features of the Report The global AI in biotechnology market provides granular level information about the market size, market share, historic market (2020 - 2024), and forecast (2025 - 2033). Annualized revenues and country level analysis for each market segment. Analysis of business strategies by identifying the key market segments positioned for strong growth in the future. The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and key strategies. The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market. The report tracks recent innovations, key developments, and start-up details that are actively working in the market. The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios. The report analyses the impact of the socio-political environment through SWOT analysis and competition through porter's five force analysis. Through study of the key business strategies and recommendations on future market approach. Comprehensive analysis of the competitive structure of the market. Demand side and supply side analysis of the market Key Players in the Global AI in Biotechnology Market Absci Corporation Antiverse AstraZeneca Cradle Bio DeepMind (Alphabet) Exscientia GenBio AI Generate Biomedicines Insilico Medicine Merck Novartis Owkin Pfizer Recursion Pharmaceuticals Roche Key Attributes: Report Attribute Details No. of Pages Forecast Period Estimated Market Value (USD) in 2025 $3.23 Billion Forecasted Market Value (USD) by 2033 $14.97 Billion Compound Annual Growth Rate Regions Covered Global Key Topics Covered: 1. Market Definition 2. Research and Methodology 3. Executive Summary 4. Global AI in Biotechnology Market - Market Dynamics 4.1 Growth Drivers 4.2 Challengers 4.3 Funding and Mergers & Acquisitions 5. Global AI in Biotechnology Market - Industry Analysis 5.1 SWOT Analysis 5.2 Porter's Analysis 6. Global AI in Biotechnology Market & Forecast (2022 - 2033) 7. Global AI in Biotechnology Market Share & Forecast (2022 - 2033) 7.1 By Offering 7.2 By Function 7.3 By Deployment Mode 7.4 By End User 7.5 By Region 7.6 By Country 8. By Offering - Global AI in Biotechnology Market & Forecast (2022 - 2033) 8.1 End-to-End Solutions 8.2 Niche Solutions 8.3 Technologies 8.4 Services 9. By End Use - Global AI in Biotechnology Market & Forecast (2022 - 2033) 9.1 Pharmaceutical Companies 9.2 Biotechnology Companies 9.3 Research Institutes & Labs 9.4 Healthcare Providers 9.5 Clinical Research Organizations 10. By Function - Global AI in Biotechnology Market & Forecast (2022 - 2033) 10.1 Research & Development 10.2 Regulatory Compliance 10.3 Manufacturing & Supply Chain 10.4 Launch & Commercial 10.5 Post Marketing Surveillance & Patient Support 10.6 Corporate 11. By Deployment Mode - Global AI in Biotechnology Market & Forecast (2022 - 2033) 11.1 Cloud-based Solutions 11.2 On-premise Solutions 12. By Region - AI in Biotechnology Market & Forecast (2022 - 2033) 12.1 North America 12.2 Europe 12.3 Asia Pacific 12.4 Latin America 12.5 Middle East & Africa 13. By Country - Global AI in Biotechnology Market & Forecast (2022 - 2033) (102 page) 13.1 United States 13.1.1 Market Size 13.1.2 Growth Drivers 13.1.3 Regulatory Policy & Reimbursements 13.2 Canada 13.3 Germany 13.4 United Kingdom 13.5 France 13.6 Italy 13.7 Spain 13.8 Switzerland 13.9 Netherlands 13.10 China 13.11 Japan 13.12 India 13.13 South Korea 13.14 Israel 13.15 Rest of the Countries (ROC) 13.15.1 Market Size 13.15.2 Growth Drivers 14. Global AI in Biotechnology Market - Key Players Profile 14.1 Business Overview 14.2 Recent Developments 14.3 SWOT Analysis 14.4 Market Strategy For more information about this report visit https://www.researchandmarkets.com/r/oy5155 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on businesswire.com: https://www.businesswire.com/news/home/20251104641468/en/ Contacts ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Insilico Medicine Frequently Asked Questions (FAQ)

  • When was Insilico Medicine founded?

    Insilico Medicine was founded in 2014.

  • Where is Insilico Medicine's headquarters?

    Insilico Medicine's headquarters is located at Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories.

  • What is Insilico Medicine's latest funding round?

    Insilico Medicine's latest funding round is Series E.

  • How much did Insilico Medicine raise?

    Insilico Medicine raised a total of $524.8M.

  • Who are the investors of Insilico Medicine?

    Investors of Insilico Medicine include Warburg Pincus, Prosperity7 Ventures, OrbiMed, Pudong Development Group, Wuxi Capital Group and 38 more.

  • Who are Insilico Medicine's competitors?

    Competitors of Insilico Medicine include METiS Technologies, AIBODY, InSilicoTrials, Aqemia, Variational AI and 7 more.

  • What products does Insilico Medicine offer?

    Insilico Medicine's products include Pharma.AI and 1 more.

  • Who are Insilico Medicine's customers?

    Customers of Insilico Medicine include Exelixis, Stemline Therapeutics , Sanofi and Tenacia.

Loading...

Compare Insilico Medicine to Competitors

Atomwise Logo
Atomwise

Atomwise develops machine learning-based discovery engines and uses artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions, and designs drugs using computational drug design. It was formerly known as Chematria. The company was founded in 2012 and is based in San Francisco, California.

Insitro Logo
Insitro

Insitro is a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology. The company has a machine learning platform that combines in vitro cellular data with human clinical data to identify insights and interventions in metabolism, oncology, and neuroscience. Insitro's approach uses technology to model disease states and design therapeutic interventions. It was founded in 2018 and is based in South San Francisco, California.

Aqemia Logo
Aqemia

Aqemia focuses on transforming the drug discovery process. The company offers technology that combines quantum-inspired physics and machine learning to scale the drug discovery process, generating a rapidly growing pipeline of new drug candidates. It primarily sells to the pharmaceutical industry. It was founded in 2019 and is based in Paris, France.

S
SOM Biotech

SOM Biotech operates as a clinical-stage drug discovery and development company that focuses on the treatment of rare Central Nervous System disorders. The company utilizes an artificial intelligence platform to discover and develop drugs, with emphasis on orphan diseases and repurposing existing drugs for new therapeutic indications. SOM Biotech's lead product has completed Phase 2b trials for Huntington's Disease. It was founded in 2009 and is based in Barcelona, Spain.

ProclaimRx Logo
ProclaimRx

ProclaimRx operates in the biopharmaceutical sector and provides AI-driven solutions for sales and marketing teams. It focuses on workflows that support healthcare professional interactions. ProclaimRx serves the biopharmaceutical industry and uses its knowledge in health tech platforms and AI to offer decision support and sales force solutions. It was founded in 2023 and is based in New York, New York.

Cradle Logo
Cradle

Cradle focuses on protein engineering in the biotechnology sector, using machine learning to optimize protein sequences. It provides tools for designing improved variants of target proteins, integrating laboratory data, and predicting performance to support research and development. Its solutions are relevant for biotech teams working on various applications, including therapeutics, enzymes, vaccines, peptides, and antibodies. It was founded in 2021 and is based in Amsterdam, Netherlands.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.